

# Selected Peer-Reviewed Publications on Hypochondroplasia

## Clinical Trial Data

### **Vosoritide Treatment for Children with Hypochondroplasia: A Phase 2 Trial**

Dauber A, Zhang A, Shankar RK et al.

[EClinicalMedicine. 2024;71:102591. Doi: 10.1016/j.eclinm.2024.102591](#)

### **Effect of Vosoritide Therapy on IGF-I and Endogenous C-type Natriuretic Peptide in Hypochondroplasia<sup>a</sup>**

Kanakatti Shankar R, Galetaki DM, Zhang A et al.

[J Clin Endocrinol Metab. 2026;111\(5\): e1421-e1426. Doi: 10.1210/clinem/dgaf591](#)

### **Phase 2 Trial of Vosoritide Use in Patients with Hypochondroplasia: A Pharmacokinetic / Pharmacodynamic Analysis<sup>a</sup>**

Galetaki D, Zhang A, Qi Y et al.

[Horm Res Paediatr. 2026;99\(1\):131-137. Doi: 10.1159/000542102](#)

## Other

### **Growth Reference Charts for Children with Hypochondroplasia**

Cheung MS, Cole TJ, Arundel Pet al.

[Am J Med Genet A 2024;194\(2\):243–252 Doi: 10.1002/ajmg.a.63431](#)

### **Parental Perception of Quality of Life and Impact of Short Stature in Children with Hypochondroplasia and Other Genetic Causes of Short Stature<sup>a</sup>**

Galetaki D, Zhang A, Rangos N et al.

[Horm Res Paediatr 2025;1-9. Doi: 10.1159/000545318](#)

### **Living With Hypochondroplasia: A Qualitative Exploration of Children's and Caregivers' Experiences, Challenges, and Unmet Needs**

Oehrlein EM, Pekala R, Cavallaro S et al.

[Mol Genet Genomic Med. 2025;13\(11\): e70151 Doi: 10.1002/mgg3.70151](#)

### **The Head Circumference Height Index (HCH-I) to Quantify Relative Macrocephaly and Aid Identification of Hypochondroplasia in Children**

Cheung MS, Lanzafame R, Low KJ et al.

[Am J Med Genet A 2026;200\(2\):353–359 Doi: 10.1002/ajmg.a.64266](#)

### **Pathways to Facilitate Early Recognition and Diagnosis of Hypochondroplasia**

Irving M, Greco E, Cocca A et al.

[Adv Ther 2026;1-16 Doi: 10.1007/s12325-026-03526-2](#)

<sup>a</sup>Not Open Access. Available upon Request

This asset is provided reactively in response to a request for scientific information and may include content about experimental or investigational compounds or indications. The content is based on available scientific evidence and clinical experience at the time of preparation and is not intended as a promotional communication.

If you would like a copy of a publication, please contact us at [medinfo@bmrn.com](mailto:medinfo@bmrn.com) or through [our web request form](#).

# B:OMARIN<sup>®</sup>

BioMarin does not support, endorse, or recommend the unapproved use of any medicine, including those discussed here. Regulatory status and approved indications of any medicine may vary between countries, please check the registration status of any medicine in your respective country. Please refer to your local prescribing information/ SmPC if the product is registered in your country.